Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report
Newly diagnosed cervical cancer with metastatic para-aortic lymph node (PALN) involvement is associated with a significantly poor prognosis, with distant metastasis being the predominant pattern of treatment failure. The programmed cell death receptor-1 (PD-1) pathway has garnered considerable atten...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573202/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173199888678912 |
|---|---|
| author | Juan Lang Juan Lang Qianqian Liu Rong Ji Miao Qiu Siben Wang Qingmeng Liu Dapeng Li Ping Chen Zhongkui Xiong Zhongkui Xiong |
| author_facet | Juan Lang Juan Lang Qianqian Liu Rong Ji Miao Qiu Siben Wang Qingmeng Liu Dapeng Li Ping Chen Zhongkui Xiong Zhongkui Xiong |
| author_sort | Juan Lang |
| collection | DOAJ |
| description | Newly diagnosed cervical cancer with metastatic para-aortic lymph node (PALN) involvement is associated with a significantly poor prognosis, with distant metastasis being the predominant pattern of treatment failure. The programmed cell death receptor-1 (PD-1) pathway has garnered considerable attention due to its role in enabling tumor cells to evade immune surveillance by eliciting the immune checkpoint response of T cells, rendering them highly refractory to conventional chemotherapy. The National Comprehensive Cancer Network (NCCN) guidelines currently recommend pembrolizumab for locally advanced cervical cancer patients positive for PD-L1 (CPS ≥1), as determined by an FDA-approved assay. Tislelizumab, an anti-PD-1 monoclonal IgG4 antibody, has been investigated in hematological malignancies and advanced solid tumors. Nevertheless, literature on regimens incorporating tislelizumab for the treatment of locally advanced cervical cancer is scarce. Herein, we present a case of a newly diagnosed high-risk, locally advanced cervical cancer patient with PALN metastases and low PD-L1 expression, treated with a combination of tislelizumab, bevacizumab, and a platinum-containing chemotherapy regimen followed by radiotherapy with maintenance therapy, resulting in a notable extension of progression-free survival. |
| format | Article |
| id | doaj-art-e624add05ca5497bb9859776f1b07f93 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-e624add05ca5497bb9859776f1b07f932025-08-20T02:19:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15732021573202Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case reportJuan Lang0Juan Lang1Qianqian Liu2Rong Ji3Miao Qiu4Siben Wang5Qingmeng Liu6Dapeng Li7Ping Chen8Zhongkui Xiong9Zhongkui Xiong10Department of Pathology, Shaoxing People’s Hospital, Shaoxing, Zhejiang, ChinaSchool of Medicine, Shaoxing University, Shaoxing, Zhejiang, ChinaDepartment of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaDepartment of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaDepartment of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaDepartment of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaDepartment of Pathology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaDepartment of Radiology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Obstetrics and Gynecology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaSchool of Medicine, Shaoxing University, Shaoxing, Zhejiang, ChinaDepartment of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaNewly diagnosed cervical cancer with metastatic para-aortic lymph node (PALN) involvement is associated with a significantly poor prognosis, with distant metastasis being the predominant pattern of treatment failure. The programmed cell death receptor-1 (PD-1) pathway has garnered considerable attention due to its role in enabling tumor cells to evade immune surveillance by eliciting the immune checkpoint response of T cells, rendering them highly refractory to conventional chemotherapy. The National Comprehensive Cancer Network (NCCN) guidelines currently recommend pembrolizumab for locally advanced cervical cancer patients positive for PD-L1 (CPS ≥1), as determined by an FDA-approved assay. Tislelizumab, an anti-PD-1 monoclonal IgG4 antibody, has been investigated in hematological malignancies and advanced solid tumors. Nevertheless, literature on regimens incorporating tislelizumab for the treatment of locally advanced cervical cancer is scarce. Herein, we present a case of a newly diagnosed high-risk, locally advanced cervical cancer patient with PALN metastases and low PD-L1 expression, treated with a combination of tislelizumab, bevacizumab, and a platinum-containing chemotherapy regimen followed by radiotherapy with maintenance therapy, resulting in a notable extension of progression-free survival.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573202/fullcervical cancerpara-aortic lymph node metastasestislelizumabbevacizumabprogrammed cell death receptor-1radiochemotherapy |
| spellingShingle | Juan Lang Juan Lang Qianqian Liu Rong Ji Miao Qiu Siben Wang Qingmeng Liu Dapeng Li Ping Chen Zhongkui Xiong Zhongkui Xiong Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report Frontiers in Immunology cervical cancer para-aortic lymph node metastases tislelizumab bevacizumab programmed cell death receptor-1 radiochemotherapy |
| title | Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report |
| title_full | Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report |
| title_fullStr | Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report |
| title_full_unstemmed | Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report |
| title_short | Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report |
| title_sort | complete remission of a high risk locally advanced cervical cancer with para aortic lymph node metastases treated with first line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy a case report |
| topic | cervical cancer para-aortic lymph node metastases tislelizumab bevacizumab programmed cell death receptor-1 radiochemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573202/full |
| work_keys_str_mv | AT juanlang completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT juanlang completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT qianqianliu completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT rongji completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT miaoqiu completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT sibenwang completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT qingmengliu completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT dapengli completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT pingchen completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT zhongkuixiong completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport AT zhongkuixiong completeremissionofahighrisklocallyadvancedcervicalcancerwithparaaorticlymphnodemetastasestreatedwithfirstlinetislelizumabplusbevacizumabcombinedwithchemotherapyfollowedbyradiotherapywithmaintenancetherapyacasereport |